Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
 |
Open Access Gold |
|
möglich sobald bei der ZB eingereicht worden ist.
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Cell Rep. Med. 5:101572 (2024)
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Acute Myeloid Leukemia ; Aml ; Car T Cell ; Cd37 ; Chimeric Antigen Receptor ; Hematopoietic Stem Cell ; Immunotherapy ; Patient-derived Xenograft; Car T-cell; Antibody-drug Conjugate; Expression; Aml; Efficacy; Siglec-6; Therapy; Protein; Cancer
ISSN (print) / ISBN
2666-3791
e-ISSN
2666-3791
Zeitschrift
Cell Reports Medicine
Quellenangaben
Band: 5,
Heft: 6,
Artikelnummer: 101572
Verlag
Cell Press
Verlagsort
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of AI for Health (AIH)
Unit for Clinical Pharmacology (KKG-EKLiP)
Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen
Fritz Bender Foundation
Research Council of Norway
Norwegian Health Authority South-East
Norwegian Cancer Society
Research Council of Norway (NFR)
University of Bergen PhD fellowship
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
Deutsche Forschungsge-meinschaft (DFG)
European Research Council
Wilhelm Sander-Stiftung
Bayerische Forschungsstiftung
m4 award of the Bavarian Ministry for Economical Affairs
Go-Bio Initiative
Ernst-Jung-Stiftung
German Cancer Aid
Else Kroner-Fresenius-Stiftung
International Doctoral Program i-Target, Immunotargeting of Cancer - Elite Network of Bavaria
Childhood Cancer Society
Research Council of Norway
Norwegian Health Authority South-East
Norwegian Cancer Society
Research Council of Norway (NFR)
University of Bergen PhD fellowship
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
Deutsche Forschungsge-meinschaft (DFG)
European Research Council
Wilhelm Sander-Stiftung
Bayerische Forschungsstiftung
m4 award of the Bavarian Ministry for Economical Affairs
Go-Bio Initiative
Ernst-Jung-Stiftung
German Cancer Aid
Else Kroner-Fresenius-Stiftung
International Doctoral Program i-Target, Immunotargeting of Cancer - Elite Network of Bavaria
Childhood Cancer Society